CD80-Mediated T-Cell Suppression by Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma
Cells · 2026
DOI: 10.3390/cells15030266 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Mian Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Peking University School and Hospital of Stomatology, Beijing 100081, China. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Neoadjuvant chemoimmunotherapy has emerged as a promising treatment strategy for head and neck squamous cell carcinoma (HNSCC). There is an urgent need to improve patient responses to this approach. In this study, we aim to elucidate the mechanisms underlying poor response to neoadjuvant chemoimmunotherapy and to identify strategies to enhance therapeutic efficacy in HNSCC. We identified a cancer stem-like cell (CSC) population enriched in patients with partial response (PR) to neoadjuvant chemoimmunotherapy, characterized by high CD80 expression. CD80 was likewise highly expressed in ALDHhighCD44+ and BMI1+ populations. Functionally, CD80 knockdown attenuated tumor-sphere-forming capacity and reduced the migration and invasion of tumor cells, whereas CD80 overexpression potentiated these pro-tumorigenic activities. Moreover, CD80 inhibition activated signaling pathways of Th1 immune responses and IL-2 production. CD80 blockade enhanced T cell cytotoxicity. In preclinical HNSCC models, inhibition of CD80 significantly decreased tumor burden, accumulated CD8+ T cells, and increased the production of cytotoxic effector molecules. Our data demonstrated that CD80 modulated tumor-cell stemness and malignant phenotype while restraining antitumor T cell immunity. Targeting CD80 augments antitumor immunity and provides a compelling strategy to enhance treatment responses to neoadjuvant chemoimmunotherapy in HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Central Laboratory, Peking University School and Hospital of Stomatology, Beijing 100081, China.
- National Clinical Research Center for Oral Diseases, Beijing 100081, China.
- National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing 100081, China.
- Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China.
ORCID-Profile: Xiyuan Ge
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- Beijing Natural Science Foundation
Zitieren
APA
Xiao, M., Qiu, L., Gao, Q., Li, R., Wang, J., Feng, Y., Li, X., & Ge, X. (2026). CD80-Mediated T-Cell Suppression by Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma. Cells. https://doi.org/10.3390/cells15030266
Vancouver
Xiao M, Qiu L, Gao Q, Li R, Wang J, Feng Y, et al. CD80-Mediated T-Cell Suppression by Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma. Cells. 2026. doi:10.3390/cells15030266
BibTeX
@article{Xiao2026,
author = {Xiao, Mian and Qiu, Lin and Gao, Qian and Li, Ruifeng and Wang, Jing and Feng, Yanrui and Li, Xuefen and Ge, Xiyuan},
title = {CD80-Mediated T-Cell Suppression by Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15030266}
}
EUVIMED